Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 30, 2025
Daily News
September 30, 2025
- Parexel Exec Says FDA Keeps Reviews on Track amid Staff Cuts, but Notes Leadership Drain
September 30, 2025
- FPMAJ Chair’s Call for Blanket Drug Price Hike: Bold Pitch or Wild Throw?
September 30, 2025
- China Approves Monthly IV Maintenance Dosing of Leqembi
September 30, 2025
- Enhertu Outperforms Kadcyla in PIII Breast Cancer Trial
September 30, 2025
- Takeda’s Oveporexton Gets Sakigake Tag for Narcolepsy Type 1
September 30, 2025
- Japan Hands Out Orphan Tags to 10 Compounds
September 30, 2025
- Alfresa, Hiroshima Univ. Hospital Begin Talks on SFTS Collaboration
September 30, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…